GlassScriptPhysician profile
Donato A Ricci
NPI 1417957432
$8,804.43
in general payments reported to CMS, 2019-2025
36 companies · $20.93 in 2025
The $20.93 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $850 · 2020: $847 · 2021: $1,570 · 2022: $1,479 · 2023: $1,886 · 2024: $2,151 · 2025: $20.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,972 · Education: $86.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,971.60 |
| Education | $86.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,654.41 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,053.18 | 2019-2024 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $603.21 | 2019-2024 | Stelara, Simponi, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $535.46 | 2019-2024 | Entyvio |
| Qol Medical, LLC | $459.89 | 2019-2024 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $373.02 | 2021-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $350.53 | 2024 | Voquezna |
| Gilead Sciences, INC. | $275.27 | 2019-2023 | |
| Genzyme Corporation | $262.52 | 2022-2024 | |
| Redhill Biopharma INC. | $240.34 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $222.17 | 2019-2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $211.27 | 2019-2024 | Linzess |
| Pfizer INC. | $204.01 | 2019-2024 | |
| Celgene Corporation | $186.06 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $152.77 | 2020-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $99.88 | 2024 | Omvoh, Zepbound |
| Daiichi Sankyo INC. | $97.10 | 2020-2023 | Injectafer |
| Celltrion USA INC. | $86.46 | 2023-2024 | Yuflyma, Zymfentra |
| Vivus LLC | $84.23 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $73.69 | 2024 | Dupixent |
| Ardelyx, INC. | $73.21 | 2023-2024 | Ibsrela |
| Madrigal Pharmaceuticals | $66.53 | 2024 | Resmetirom |
| Ethicon US, LLC | $59.90 | 2020-2023 | Linx Reflux Management System |
| Allergan, INC. | $55.92 | 2019-2020 | |
| Braintree Laboratories, INC. | $47.24 | 2021-2023 | Suflave, Sutab |
| Medtronic, INC. | $46.08 | 2021 | |
| Enterra Medical, INC. | $43.14 | 2023 | |
| Aimmune Therapeutics, INC. | $36.78 | 2024 | |
| Organon LLC | $24.85 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $24.42 | 2019 | |
| Amgen INC. | $22.80 | 2023 | Amjevita, Avsola |
| Ipsen Biopharmaceuticals, INC | $20.29 | 2024 | Iqirvo |
| Shionogi INC | $18.42 | 2019 | |
| Fresenius Kabi USA, LLC | $15.29 | 2023 | Idacio |
| Alfasigma USA, INC. | $12.87 | 2020 | |
| Shire North American Group INC | $11.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donato Ricci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.